Tuesday, August 27, 2013

IT'S IN THE NEWS!

JAKAFI (RUXOLITINIB)IMPROVED SURVIVAL WHEN GIVEN WITH XELODA IN RECURRENT AND REFRACTORY METASTATIC PANCREATIC CANCER,OPENING NEW DOORS TO NEW CLINICAL TRIALS IN THIS DISEASE!

JAKAFIRuxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer


Published Online: Friday, August 23, 2013
Jakafi

The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib (Jakafi) and the chemotherapy agent capecitabine compared to patients who were treated with capecitabine alone, according to results of a phase II proof-of-concept study.

The drug’s manufacturer, Incyte, announced the results on Wednesday. Full results from the study are expected to be presented at a future scientific meeting.

Ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor that was approved by the FDA in 2011 for the treatment of myelofibrosis, a form of blood cancer characterized by bone marrow failure and spleen enlargement.
- See more at: http://www.targetedhc.com/articles/Ruxolitinib-Improves-Survival-When-Given-with-Capecitabine-in-Recurrent-or-Refractory-Pancreatic-Cancer#sthash.P1CrDDpt.dpuf

Ruxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer


Published Online: Friday, August 23, 2013
Jakafi

The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib (Jakafi) and the chemotherapy agent capecitabine compared to patients who were treated with capecitabine alone, according to results of a phase II proof-of-concept study.

The drug’s manufacturer, Incyte, announced the results on Wednesday. Full results from the study are expected to be presented at a future scientific meeting.

Ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor that was approved by the FDA in 2011 for the treatment of myelofibrosis, a form of blood cancer characterized by bone marrow failure and spleen enlargement.
- See more at: http://www.targetedhc.com/articles/Ruxolitinib-Improves-Survival-When-Given-with-Capecitabine-in-Recurrent-or-Refractory-Pancreatic-Cancer#sthash.P1CrDDpt.dpuf

Ruxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer


Published Online: Friday, August 23, 2013
Jakafi

The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib (Jakafi) and the chemotherapy agent capecitabine compared to patients who were treated with capecitabine alone, according to results of a phase II proof-of-concept study.

The drug’s manufacturer, Incyte, announced the results on Wednesday. Full results from the study are expected to be presented at a future scientific meeting.

Ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor that was approved by the FDA in 2011 for the treatment of myelofibrosis, a form of blood cancer characterized by bone marrow failure and spleen enlargement.
- See more at: http://www.targetedhc.com/articles/Ruxolitinib-Improves-Survival-When-Given-with-Capecitabine-in-Recurrent-or-Refractory-Pancreatic-Cancer#sthash.6YZwYBXR.dpuf

Ruxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer


Published Online: Friday, August 23, 2013
Jakafi

The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib (Jakafi) and the chemotherapy agent capecitabine compared to patients who were treated with capecitabine alone, according to results of a phase II proof-of-concept study.

The drug’s manufacturer, Incyte, announced the results on Wednesday. Full results from the study are expected to be presented at a future scientific meeting.

Ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor that was approved by the FDA in 2011 for the treatment of myelofibrosis, a form of blood cancer characterized by bone marrow failure and spleen enlargement.
- See more at: http://www.targetedhc.com/articles/Ruxolitinib-Improves-Survival-When-Given-with-Capecitabine-in-Recurrent-or-Refractory-Pancreatic-Cancer#sthash.6YZwYBXR.dpuf
Post a Comment